DISP-10 / Dispatch Biotherapeutics - LARVOL DELTA

Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers (Businesswire) - "The participant was treated with both DV-10 and ide-cel components of DISP-10 and completed the protocol-defined dose-limiting toxicity (DLT) evaluation period. Additionally, DISP-10 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced GI cancers....The first-in-human, Phase 1, multicenter, open-label clinical study is designed to evaluate the safety, tolerability, and activity of DISP-10."

Fast track • First-in-human • Trial status • Colorectal Cancer • Esophageal Adenocarcinoma • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Dispatch Biotherapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Dispatch Biotherapeutics

New P1 trial • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors (Businesswire) - "Program leverages Dispatch’s first-in-class Flare platform, designed to address key barriers limiting immunotherapy efficacy in solid tumors. Phase 1 clinical study expected to initiate patient enrollment in coming months."

IND • New P1 trial • Solid Tumor

Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting (Businesswire) - "Dispatch’s Flare platform addresses these barriers by systemically delivering a tumor-specific virus that paints a universal synthetic antigen (Flare) on tumor cells, enabling precise recognition by T cells, while reshaping the tumor microenvironment to support immune activity. Data presented at SITC (Abstract 394) demonstrate strong and consistent tumor labeling, iterative viral amplification and tumor cell clearance across multiple epithelial tumor models...The company also presented preclinical findings from DISP-10, its first therapeutic candidate (Abstract 393)....DISP-10 demonstrated potent anti-tumor responses in numerous in vitro and in vivo models, with no activity observed in healthy cells."

Preclinical • Solid Tumor

DISP-10 is a novel CAR T and tumor-specific virus combination undergoing clinical development that is designed for use as a universal treatment for epithelial tumors (SITC 2025) - "Expression and function of IL18 and CXCL9 was also confirmed. Virus-mediated target delivery and subsequent recognition by CAR T cell led to a strong anti-tumor response across models, including NSG mouse models and primary human tumor samples.Conclusions Based on the promising preclinical efficacy and safety/specificity profile of this novel therapeutic, a Phase I study is planned to test this strategy in multiple solid tumors."

Clinical • IO biomarker • Oncology • Solid Tumor • CXCL9 • IL18

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors (Businesswire) - "Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to initiate in 2026."

Commercial • New P1 trial • Solid Tumor

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy (Yahoo News) - "A new biotechnology company debuted Wednesday with a hefty bankroll and an immunotherapy approach it claims has the potential to treat an array of tough-to-reach solid tumors....It has since raised $216 million and developed a lead program that’s expected to enter clinical testing next year."

Financing • New trial • Solid Tumor